Equitable Access to GLP-1 Receptor Agonists—Essential but Not Accessible
JAMA · 01.10.2026
DOI: 10.1001/jama.2026.15762 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, online erschienen am 01.10.2026. Verfasst von Safura Abdool Karim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
This Perspective discusses the actions needed to improve accessibility of glucagon-like peptide-1 (GLP-1) receptor agonists, especially in low- and middle-income countries, after their addition to the World Health Organization’s (WHO) Model List of Essential Medicines.
Autor:innen und Institutionen
- Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
- Johns Hopkins Berman Institute of Bioethics, Baltimore, Maryland.
- Council on Foreign Relations, Washington, DC.
Zitieren
APA
Abdool Karim, S., Faden, R. R., Searchinger, C., & Bollyky, T. J. (2026). Equitable Access to GLP-1 Receptor Agonists—Essential but Not Accessible. JAMA. https://doi.org/10.1001/jama.2026.15762
Vancouver
Abdool Karim S, Faden RR, Searchinger C, Bollyky TJ. Equitable Access to GLP-1 Receptor Agonists—Essential but Not Accessible. JAMA. 2026. doi:10.1001/jama.2026.15762
BibTeX
@article{AbdoolKarim2026,
author = {Abdool Karim, Safura and Faden, Ruth R and Searchinger, Chloe and Bollyky, Thomas J},
title = {Equitable Access to GLP-1 Receptor Agonists—Essential but Not Accessible},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.15762}
}
EUVIMED